Does Rallies show Form 4 insider transactions for RXST?

Yes. Rallies tracks RXST insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is RXST research on Rallies investment advice?

No. Rallies provides research, data, and educational context for RXST. It does not provide personalized investment advice.

RXST (RxSight, Inc. Common Stock) Stock Analysis - Insider Trades

RxSight, Inc. Common Stock (RXST) is a publicly traded Healthcare sector company. As of May 21, 2026, RXST trades at $6.02 with a market cap of $248.38M and a P/E ratio of -5.38. RXST moved +3.53% today. Year to date, RXST is -41.11%; over the trailing twelve months it is -62.94%. Its 52-week range spans $5.30 to $55.57. Analyst consensus is neutral with an average price target of $9.83. Rallies surfaces RXST's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading RXST stock inside the company?

Recent RXST insider activity includes Fountain Tamara sold 7.00K, Maniar Shweta sold 3.52K, Corley Jesse Anderson bought 1.77K, Corley Jesse Anderson bought 1.44K, and Goldshleger Ilya sold 3.10K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

RXST Key Metrics

Key financial metrics for RXST
Metric	Value
Price	$6.02
Market Cap	$248.38M
P/E Ratio	-5.38
EPS	$-1.13
Dividend Yield	0.00%
52-Week High	$55.57
52-Week Low	$5.30
Volume	103
Avg Volume	0
Revenue (TTM)	$127.48M
Net Income	$-46.64M
Gross Margin	77.02%

Recent RXST Insider Trades

Fountain Tamara sold 7.00K (~$180.00K) on Mar 12, 2025.
Maniar Shweta sold 3.52K (~$108.62K) on Jan 22, 2025.
Corley Jesse Anderson bought 1.77K (~$55.00K) on Jan 16, 2025.
Corley Jesse Anderson bought 1.44K (~$45.00K) on Jan 15, 2025.
Goldshleger Ilya sold 3.10K (~$143.08K) on Nov 29, 2024.

Latest RXST News

RxSight Q1 Sales Fall 18.5% to $30.9M While Installed Base Tops 1,154 — May 6, 2026
RxSight Hits 300,000 Implants, Reports 93.1% 20/20 Clinical Outcomes — Apr 8, 2026
RxSight narrows Q4 loss to $0.03, posts $32.6M revenue beat — Feb 26, 2026
RxSight Expands Installed Base 20% After 12% Procedure Growth, Appoints New CFO — Jan 14, 2026

RXST Analyst Consensus

9 analysts cover RXST: 0 strong buy, 1 buy, 7 hold, 1 sell, 0 strong sell. Consensus rating is neutral. Average price target: $9.83.

Common questions about RXST

Who is trading RXST stock inside the company?: Recent RXST insider activity includes Fountain Tamara sold 7.00K, Maniar Shweta sold 3.52K, Corley Jesse Anderson bought 1.77K, Corley Jesse Anderson bought 1.44K, and Goldshleger Ilya sold 3.10K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for RXST?: Yes. Rallies tracks RXST insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is RXST research on Rallies investment advice?: No. Rallies provides research, data, and educational context for RXST. It does not provide personalized investment advice.